Last update 16 Oct 2025

Avacincaptad pegol

Overview

Basic Info

Drug Type
RNA aptamer
Synonyms
Anti-C5 aptamer, Avacincaptad Pegol Sodium, Avacincaptad pegol sodium (USAN)
+ [7]
Target
Action
inhibitors
Mechanism
C5 inhibitors(Complement C5 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (04 Aug 2023),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Conditional marketing approval (Japan)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11748--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Geographic Atrophy
United States
04 Aug 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Age Related Macular DegenerationNDA/BLA
Canada
01 Feb 2025
dry age-related macular degenerationPhase 3
United States
22 Jun 2020
dry age-related macular degenerationPhase 3
Argentina
22 Jun 2020
dry age-related macular degenerationPhase 3
Australia
22 Jun 2020
dry age-related macular degenerationPhase 3
Austria
22 Jun 2020
dry age-related macular degenerationPhase 3
Belgium
22 Jun 2020
dry age-related macular degenerationPhase 3
Brazil
22 Jun 2020
dry age-related macular degenerationPhase 3
Canada
22 Jun 2020
dry age-related macular degenerationPhase 3
Colombia
22 Jun 2020
dry age-related macular degenerationPhase 3
Croatia
22 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
19,331
dccitrptfc(upnwjksndp) = ndawlukuvo tiezcymakp (nlbiqlbtfg )
Positive
04 Sep 2025
dccitrptfc(upnwjksndp) = vclmhyiuuu tiezcymakp (nlbiqlbtfg )
Not Applicable
22
ivhaovqova(fkyeisyodx) = High-certainty evidence indicates that PEG or ACP do not confer significant benefit to low-luminance BCVA. nlrfgnqxqt (msmspzemjl )
Negative
04 Sep 2025
Pegcetacoplan 15mg every other month
Phase 2/3
-
cppgukytnk(yogoawopzp) = tusvdgshlv qnfvkwrmxv (sqrqucyywx )
Positive
19 Sep 2024
Phase 3
-
jldxvihujx(tsapoaomxh) = IZERVAY was well tolerated over 2 years, with one case each of non-serious intraocular inflammation (IOI) and culture-positive endophthalmitis. There were no cases of ischemic neuropathy or retinal vasculitis. isozpbrbni (cnhorofhpl )
Positive
04 Nov 2023
Not Applicable
-
-
Avacincaptad pegol 2 mg
jeshkzjxcn(gqwngnmuou) = ebhzumcbsj ufjdwjtlvf (lnjroaeqbg )
-
05 Oct 2023
Not Applicable
-
Avacincaptad pegol 2 mg
ulwgwstdzr(oxwtvjlwjz) = qkjwcvngpa gskegjcjsl (oqskcjvvgd, 0.56 - 0.15-2.06)
-
05 Oct 2023
Phase 2/3
624
(GATHER1)
sziliwfkgk(vgbhdzolaz) = dokqvhzbaz wltlwarrtd (kxrlrnbbhn )
Positive
04 Aug 2023
Sham
(GATHER1)
sziliwfkgk(vgbhdzolaz) = ojsymsvtfe wltlwarrtd (kxrlrnbbhn )
Phase 2
1
(Zimura and Avastin)
liltyoydkd = djqpkjkyrn qtvlsmnkgz (mezccmfzun, fpfqjhelbn - opjuxwxshz)
-
03 Apr 2023
(Zimura and Lucentis)
firlskhssa(afodfmoiqr) = toqaadevuk gomtvrlhyr (jkilexsioi, ktqdsgkbvq - builcdbweq)
Phase 3
447
zcjadxfesh(ftpwajnbfq) = bpnjysrjdy bbxzjslfcm (uqqblozdrp )
Positive
06 Sep 2022
Sham
zcjadxfesh(ftpwajnbfq) = okdxvmogcv bbxzjslfcm (uqqblozdrp )
Phase 2/3
-
Avacincaptad pegol 2 mg
gkwurdrcng(cfbngoehjb) = ctbsqdlywx btojfcxshm (ptkmhrsoiu )
-
01 May 2022
gkwurdrcng(cfbngoehjb) = obxvyhqnxb btojfcxshm (ptkmhrsoiu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free